Capstone Holding Corp. · NASDAQ:CAPS

Capstone — Capstone Therapeutics — Technical Presentation (December 2010)

18 slides from Capstone's technical presentation, Dec 14, 2010

  1. Slide 1: AZX100 Dermal Scarring Clinical Development Program

    AZX100 AZX100 Dermal Scarring Clinical Development Program 14-Dec-2010 AZX100

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements in this presentation or otherwise attributable to Capstone Therapeutics regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, whi

  3. Slide 3: Dermal Scarring: Range of Indications

    Dermal Scarring: Range of Indications Keloid Scars • Overgrowth of dense fibrous tissue • Extend beyond borders of original wound • Do not regress spontaneously • Tend to recur after excision Hypertrophic Scars • Red, itching, raised fibrous lesions • Typically do not expand beyond boundaries of ini

  4. Slide 4: Keloid Scars

    Keloid Scars

  5. Slide 5: What are the Goals of Phase 2a?

    What are the Goals of Phase 2a?

  6. Slide 6: Phase 2a Clinical Trials - Keloid Scars

    AZX100 Phase 2a Clinical Trials - Keloid Scars

  7. Slide 7: Phase 2a Clinical Trials - Keloid Scars

    AZX100 Phase 2a Clinical Trials - Keloid Scars

  8. Slide 8: Phase 2a Results - Keloid Scars

    AZX100 Phase 2a Results - Keloid Scars Summary

  9. Slide 9: Where was AZX100 "better"?

    Where was AZX100 “better”? Outcomes & Time Points at which AZX100 1.0mg/cm was “better” than placebo (not statistically significant)

  10. Slide 10: OL-ASCAR-05 - 12-Month Analysis - 1.0 mg/cm Dose Group vs. Placebo

    AZX100 OL-ASCAR-05 - 12-Month Analysis - 1.0 mg/cm Dose Group vs. Placebo Mean Scar Width (mm) by Visit by Treatment Group Not statistically significant; for illustrative purposes only

  11. Slide 11: OL-ASCAR-05 - 12-Month Analysis - 1.0 mg/cm Dose Group vs. Placebo

    AZX100 OL-ASCAR-05 - 12-Month Analysis - 1.0 mg/cm Dose Group vs. Placebo Mean Scar Maximum Elevation (mm) by Visit by Treatment Group Not statistically significant; for illustrative purposes only

  12. Slide 12: CAPSTONE

    CAPSTONE

  13. Slide 13: Phase 2a Clinical Trials - Surgical (Trocar Site) Scars

    AZX100 Phase 2a Clinical Trials - Surgical (Trocar Site) Scars

  14. Slide 14: Phase 2a Clinical Trial in Surgical (Trocar Site) Scars

    AZX100 Phase 2a Clinical Trial in Surgical (Trocar Site) Scars

  15. Slide 15: CAPSTONE

    CAPSTONE

  16. Slide 16: Is AZX100 a Viable Candidate for Clinical & Commercial Development?

    Is AZX100 a Viable Candidate for Clinical & Commercial Development?

  17. Slide 17: Is AZX100 a Viable Candidate for Clinical & Commercial Development?

    Is AZX100 a Viable Candidate for Clinical & Commercial Development?

  18. Slide 18: NASDAQ CM: CAPS

    N ASDAQ CM: CAPS www.capstonethx.com Capstone Therapeutics 1275 West Washington Street - Suite 101 Tempe, AZ 85281 (602) 286-5520

Capstone Therapeutics — Technical Presentation (December 2010) on 6ix